Introduction
Gastrointestinal stroma tumours (GIST) are a subgroup of soft tissue sarcomas (STS) that used to have a poor prognosis. However, in the past decade the treatment of GISTs has changed radically with the introduction of the tyrosine kinase inhibitor (TKI) imatinib (Glivec ® , Novartis Pharma GmbH, Nuremberg, Germany) [1] . This development of a targeted therapy for treating GIST can also be applied as a model for the treatment of other can-
Why Treat GIST with Imatinib?
In addition to inhibiting BCR-ABL, STI 571 can inhibit other TK such as KIT and platelet-derived growth factor receptor (PDGFR)-α/β [6] , as shown using in vitro and animal models [3] . The proto-oncogene c-kit encodes KIT, a growth factor with TK activity, the ligand of which is the stem cell factor (SCF) [7, 8] . GIST cells also express KIT [8] . Hirota et al. [7] detected gain-of-function mutations in c-kit in GIST, resulting in constitutive activation of KIT independent of SCF. Gain-of-function mutations can be found in most GIST (more than 90%) and apparently contribute considerably to the development of these tumours [8] . Thus, it seemed to be reasonable to treat GIST with the TKI imatinib, especially as GIST are generally unresponsive to chemotherapy [8] .
The first patient with metastatic GIST treated with imatinib was a middle-aged Finnish woman who had not responded to previous therapies [8] . She received 400 mg imatinib (4 100-mg capsules) daily. 1 month after beginning treatment with the TKI she had a complete metabolic response identified by positron-emission tomography (PET) and magnetic resonance imaging (MRI). Side effects, such as dyspepsia and increased frequency of bowel movements, were rare and mild. These encouraging results led to a successful evaluation of the efficacy and safety of imatinib in a clinical study program, resulting in approval of the TKI for treating GIST within 2 years.
Treatment with Imatinib -Evaluating Efficacy and Safety in Clinical Trials
Based on the promising treatment result in 'patient zero', the Finnish-American open-label, randomised, multicentre phase II study (B2222) was initiated. The study population consisted of 147 patients with advanced GIST [9] . They were randomised to receive 400 or 600 mg imatinib once daily. After a follow-up of at least 9 months, 120 (81.6%) patients still remained in the study. A partial response (PR) was seen in 36 of 73 (49.3%) patients given 400 mg imatinib and in 43 of 74 taking 600 mg imatinib, giving a total of 79 out of 147 patients (53.7%). The most frequent adverse events (AE) were oedema or fluid retention, nausea, diarrhoea, myalgia, fatigue or dermatitis/rash. In a further analysis after a follow-up for up to 71 months, the overall response rates (ORR) were comparable in both arms [10] . The median time to progression was 24 months for all patients; 20 months in the 400 mg arm and 26 months in the 600 mg arm. The median overall survival (OS) for all patients was 57 months.
In Europe, a dose-finding phase I study including 36 patients with metastatic GIST started soon after the Finnish-American study [11] . Patients were treated with imatinib at once daily doses of 400 mg (n = 8) and 300 mg (n = 8), twice daily 400 mg (n = 16) or 500 mg (n = 8). Within 8 weeks of treatment, dose-limiting toxic effects were observed in 5 patients on the highest imatinib dose of 500 mg twice daily. Those effects included grade 3 nausea and/or vomiting (n = 3), grade 3 oedema (n = 1), and grade 3 dyspnoea (n = 1). The most frequent AE were skin rash (n = 22) that led to dose modification in 2 patients, oedema (n = 30) and nausea (n = 17). In 25 of the 36 patients with GIST, an objective response (OR) was observed, 19 with confirmed PR, and 6 with unconfirmed PR or a 20-29% regression according to RECIST. 7 patients had stable disease (SD) and 4 progressed under treatment. Consequently, the maximum tolerated dose for future studies was defined as 400 mg twice daily.
Another phase II study included 51 patients, of whom 27 had GIST and 24 had other STS [12] . All patients received 400 mg imatinib twice daily. The median time on treatment was 13+ months for patients with GIST and 2 months for patients with other STS. The most common AE were anaemia (92%), oedema (84%), skin rash (69%), fatigue (76%), nausea (57%), granulocytopenia (47%) and diarrhoea (47%). Side effects were mostly mild to moderate and quite often observed in the first 8 weeks of treatment. Complete responses (CR) were seen in 4% of patients with GIST, PR in 67%, SD in 18% and progression (PD) in 11%. No OR was seen in patients with other STS. This established that imatinib was exclusively active in GIST.
Phase III Studies Confirm the Efficacy and Safety of Imatinib in GIST Patients
Based on the results of the previous studies, 2 phase III trials were conducted. In the trial EORTC 62005, eligible patients had histologically confirmed advanced or metastatic KIT-expressing GIST [13] . Altogether 946 patients were recruited in less than 1 year, and they were randomly assigned to receive either 400 mg once daily (n = 473) or 400 mg twice daily (800 mg, n = 473). This represented the standard dose and maximum tolerated dose based on the EORTC phase I study. The primary endpoint was progression-free survival (PFS). At a median follow-up of 25.3 months, 56% of patients in the 400 mg group had progressed, in the 800 mg group 50% had progressed (estimated hazard ratio (HR) 0.82; 95% confidence interval (CI) 0.69-0.98; p = 0.026). Response rates did not differ between treatment groups, CR was observed in 52 patients (5%), PR in 442 patients (47%) and SD in 300 patients (32%). OS rates at 1 year were 85% in the 400 mg imatinib group and 86% in the 800 mg imatinib group; the rates at 2 years were 69% and 74%, respectively. AE occurred frequently but were mostly mild or moderate. Dose reductions were more often seen in the 800 mg group (60%) versus the 400 mg group (16%), as were treatment interruptions (64% vs. 40%). Thus, it seemed that 400 mg was as effective as 800 mg of imatinib in reaching OR, but at the higher dose the PFS was significantly better.
The other phase III study (S0033) included 694 North American patients with KIT-positive advanced GIST [14] . The patients were randomly assigned to groups that received either 400 mg imatinib once daily (n = 345) or twice daily (800 mg, n = 349). The primary endpoint was PFS. The median follow-up was 4.5 years and the median PFS was similar in both groups: 18 months in the 400 mg group and 20 months in the 800 mg group. The median OS also did not differ between cohorts, at 55 and 51 months, respectively. The higher dose was associated with more frequent high-grade toxicities (162 vs. 120 grade 3 AE, 27 vs. 48 grade 4 AE and 2 vs. 9 grade 5 AE). The authors concluded that 400 mg imatinib once daily is the standard dosage for treating patients with advanced or metastatic GIST. After 8 years 189 patients were still alive [15] . The estimated 10-year OS rate was 23% (95% CI 20-26%).
At the ASCO Annual Meeting in 2011, von Mehren et al. [16] presented the long-term results of the aforementioned phase II study B2222, featuring 56 patients (38%) that had continued imatinib therapy for more than 3 years. The median follow-up was 9.4 years. The PFS did not differ between patients regardless of whether they had a CR, PR, or SD as the best response, and was 9 years. It appeared that patients with SD after treatment with imatinib for more than 8 years might have a normal life expectancy.
Regarding the question of how long patients with GIST should be treated with imatinib, in the BFR14 trial (n = 434) subset of patients were randomised to stop imatinib after 1 year of treatment (n = 58), after 3 years (n = 50), and after 5 years (n = 27) once a CR, PR or SD was reached [17] . After stopping imatinib a rapid progression was observed; the PFS was significantly better in patients with continuous imatinib treatment. The authors concluded that imatinib treatment should not be interrupted in GIST patients.
Looking for Prognostic or Predictive Factors to Optimise Imatinib Treatment
The Gastrointestinal Stromal Tumor Meta-Analysis Group conducted a meta-analysis based on the data of the 2 previously mentioned phase III trials [18] with the aim of identifying possible prognostic and predictive factors. The meta-analysis included 1,640 patients with advanced GIST and compared the 400 mg dose (n = 818) to the 800 mg dose of imatinib (n = 822). After a median follow-up of 45 months the PFS was slightly, but significantly, better in patients on the 800 mg dose (estimated HR 0.89, p = 0.04). However, the OS was not different between the dosage groups (HR 1.00; p = 0.97). Mutation status was known for a subset of 772 patients; those with mutations in exon 9, other mutations, or were wild type had a worse prognosis compared to patients with exon 11 mutations. However, it was shown that patients with exon 9 mutations had better PFS when receiving the higher dosage of 400 mg twice daily (800 mg).
Since not all patients respond to imatinib treatment, a retrospective trial investigated whether surgical cytoreduction before starting imatinib could influence the prognosis of GIST patients [19] . Of 249 patients, 62 patients had surgery and 187 received imatinib immediately as first-line treatment. The median followup was 44 months. The surgical cytoreduction did not lead to a significantly better outcome in terms of improved PFS or OS; however, PFS tended to be better in the cytoreduction cohort (53.9 vs. 33.9 months). Factors that were related to PFS included mutational status, tumour size, and granulocyte count at presentation. Factors associated with OS were age and tumour size. Dose escalation of imatinib was evaluated as a possible strategy in patients who had disease progression on 400 mg of imatinib per day. A subset of 133 patients in the EORTC 62005 study crossedover from 400 mg once to 400 mg twice daily according to the protocol [20] : 3 (2%) of these had CR and 36 (27%) SD. The median PFS was 81 days. In the S0033 trial, 117 patients crossed-over to the higher imatinib dosage [14] : 3 patients (3%) achieved PR and 33 patients (28%) SD. A possible explanation for these results might be exon 9 mutation status or insufficient imatinib blood levels.
Interestingly, Demetri et al. [21] showed that imatinib plasma levels are variable and do not have a reliable correlation with the dose. They also found that plasma levels of imatinib could influence prognosis, as patients with the lowest imatinib plasma levels had a higher risk for rapid progression compared to patients with higher plasma levels (11.3 months vs. more than 30 months, p = 0.0029). The cut-off for this effect was a plasma level of imatinib of 1,100 ng/ml.
These studies therefore showed that imatinib is the standard first-line therapy for advanced/metastatic GIST.
Imatinib in the Neo-/Adjuvant Setting
An analysis of pooled population-based cohorts of patients with operable GIST without adjuvant therapy was conducted to investigate risk-stratification schemes [22] . The analysis was based on data from 2,560 patients. The estimated 15-year recurrence-free survival (RFS) after surgery was 59.9%. Large tumour size, high mitosis count, non-gastric location, presence of rupture, and male sex were identified as factors for a poor prognosis. The authors developed contour maps based on tumour size, tumour site, mitosis count, and rupture, to estimate the risk of relapse after surgery. These maps take into account the continuous and non-linear nature of tumour size and mitosis count, so the risk of recurrence could be estimated in a more precise way.
The impact of imatinib as adjuvant therapy was evaluated in 3 randomised studies. 713 patients with a completely removed KITpositive GIST of at least 3 cm, and independent of the mitotic rate, were included in a double-blind, placebo-controlled American phase III trial [23] . Patients were then randomised 1: 1 either to imatinib 400 mg per day (n = 359) or to placebo (n = 354) for 1 year. Cross-over was allowed. At a median follow-up of 19.7 months the RFS at 1 year was highly significant better in the imatinib arm than in the placebo arm (98% vs. 83%; HR 0.35; 95% CI 0.22-0.53; p < 0.0001). Based on these results imatinib was approved for adjuvant therapy of GIST in December 2008 in the USA and in Europe in April 2009.
To compare the effectiveness of adjuvant treatment with imatinib for 1 year compared to 3 years, 397 patients with GIST and a high risk for recurrence after surgery were grouped to adjuvant treatment with imatinib 400 mg daily for either 12 (n = 199) or 36 months (n = 198) [24] . The treatment started within 12 weeks following surgery. At a median follow-up of 54 months after randomisation, the longer adjuvant imatinib treatment was associated with better RFS compared to the shorter adjuvant imatinib treatment (65.6% vs. 47.9%; HR 0.46; 95% CI 0.32-0.65; p < 0.001). The OS was also significantly longer in the 36-month group, which is particularly relevant. At 5 years 92% of patients in the 3-year arm were still alive compared to 81.7% in the 1-year arm. Analyses at the median follow-up of 7.5 years confirmed the RFS and OS results, still showing a significant benefit for the 3-year group [25] . The third randomised study was a phase III intergroup trial from the EORTC, which included 908 patients who were randomised to either 2 years of adjuvant treatment with imatinib (n = 454) or observation (n = 454). Eligible patients had an intermediate or a high risk of recurrence corresponding to the consensus criteria. Primary endpoint was the imatinib failure-free survival (IFFS) [26, 27] . The 5-year IFFS tended to be better for high-risk patients in the imatinib compared to the observation group, but did not reach statistical significance. By contrast, RFS (secondary endpoint) was significantly better in the imatinib group (p < 0.001).
Impact of Primary Mutations on Adjuvant Therapy
Mutation testing is now a substantial part in the decision process for adjuvant therapy. The mutational status represents a considerable prognostic factor and the response to imatinib differs depending on the mutation. Consequently, assessing the mutational status is mandatory prior to starting an adjuvant therapy. When a KIT exon 9 mutation is detected the optimal dosing of imatinib has yet to be defined. However, as the higher dosage of 800 mg results in a response and a PFS almost 3 times higher compared to the dosage of 400 mg, it might be reasonable to apply the higher dosage in the adjuvant setting. Indeed, according to expert opinion, patients with an exon 9 mutation could profit from the higher dose [28] .
Patients with wild-type GIST represent a heterogeneous group within whom the activating mutations in Kit or PDGFRα cannot be detected. In the SSGXVIII study, in a rather small number of patients, no treatment modality demonstrated superiority [24] . If a succinate dehydrogenase deficiency or an association with neurofibromatosis type 1 is identified, then imatinib is not effective due to molecular alterations. Therefore, the decision for, or against, an adjuvant therapy should be taken individually together with the patient [29] .
Patients with the exon 18 mutation D842V of PDGFRα (affecting 20% of patients with localised GIST in the stomach) should not receive an adjuvant therapy, independent of the recurrence risk. Tumours with this mutation do not respond to imatinib either in vitro or in vivo; at least in these patients the course of the disease is indolent. Patients with other mutations of PDGFRα should be considered for an adjuvant therapy based on their risk of recurrence.
Neoadjuvant Therapy
In situations when a R0 resection is not possible, or when a reduction of tumour mass enables a less mutilating operation, the standard is to treat pre-operatively. This is particularly true for GIST located in the gastroesophageal junction, the duodenum or the rectum. Mutational analysis should be performed to exclude insensitive mutations and to define the correct dosage to achieve the best possible response. The removal of the tumour should take place when optimal tumour regression is achieved, usually after 6-12 months. The first study of imatinib in the neoadjuvant setting was conducted by the Radiation Therapy Oncology Group (RTOG) in the USA [30] . 52 patients with analysable data were included in the trial. They had local advanced or operable metastatic GIST. Participants received imatinib 600 mg/day for 8-12 weeks. Operation took place when at least the condition of SD had been reached. Afterwards the patients continued to receive imatinib at the same dose for another 2 years. An R0 resection was possible in 77% of the cases, but no conversion rate was reported. The 5-year PFS rate was 56%, the 5-year OS 77%.
The biggest study evaluating pre-operative therapy with imatinib took place in Germany (the Apollon trial). It included patients with potentially resectable tumours that also required a multi-visceral resection or those for whom an R0 resection could not definitely be achieved [31] . Treatment duration was 6 months. 45 patients were included and 42 were treated per protocol. After imatinib therapy, 40 of 42 patients were symptom free. In 87% of the cases an R0 resection could be performed. For most patients a less extensive operation was possible owing to a reduction in the pre-operative tumour mass. Regression of median tumour size was highly significant; size reduced from 10.8 to 4.6 cm in the imatinib arm (p < 0.001). The 5-year PFS rate was 67% and the 5-year OS 83%.
Neoadjuvant therapy with imatinib is safe and results in a significant decrease of tumour mass, leading to a significant reduction in operative morbidity. Long-term data are promising.
Recommendations for the Use of Imatinib in GIST
Imatinib is the standard first-line therapy for advanced/metastatic GIST. The dosage is 400 mg daily, except for patients with mutations in exon 9 of c-kit who should be treated with 800 mg daily. The treatment should not be interrupted and should be taken continuously [29] . In the adjuvant setting, a 3-year treatment with imatinib is recommended for patients with a significant risk of relapse [29] . The recommended dosage of imatinib is also 400 mg, although where there is a KIT exon 9 mutation a dosage of 800 mg might be the better choice, but the optimal dosage has yet to be defined. Neoadjuvant treatment with imatinib is feasible and should be given for at least 6 months whenever a response would affect surgery.
The only contraindication for the initial use of imatinib is hypersensitivity to the active substance or to any of the excipients [32] . Common adverse reactions of imatinib are nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash [32] . Additionally, (severe) fluid retention has been reported leading to oedema, ascites, etc.; anorexia may also occur. Therefore, it is recommended that patients should be weighed regularly while taking imatinib. Haematological alterations such as anaemia, neutropenia or thrombocytopenia have also been observed, as well as an increase in hepatic enzymes as a possible adverse reaction. Optimal patient management should include regular laboratory tests, such as a complete blood count and monitoring of liver function. Patients should also be monitored for the appearance of gastrointestinal or intra-tumour haemorrhages. The appearance of adverse reactions may be appropriately managed by dose adjustments.
The biotransformation of imatinib is generally catalysed by the cytochrome P450 (CYP) enzyme 3A4 (CYP3A4) [32] . Inhibitors of CYP3A4 activity could increase the imatinib plasma concentrations significantly; these include protease inhibitors such as indinavir or lopinavir/ritonavir, azole antifungals including ketoconazole or itraconazole, and certain macrolides such as erythromycin or clarithromycin. In contrast, inducers of CYP3A4 activity, such as dexamethasone, carbamazepine and rifampicin, may significantly decrease imatinib plasma concentrations. Furthermore, imatinib can alter the concentration of drugs like simvastatin, cyclosporine, fentanyl, bortezomib, and docetaxel. Food seems to have no or only a little impact on the resorption of imatinib, although a high fat diet may decrease it slightly.
A complete description of interactions, potential adverse reactions, and interventions that can be taken to prevent or to treat adverse reactions can be found in the summary of product characteristics of imatinib (Glivec ® ).
Mechanisms of Resistance to Imatinib
A clinical challenge in the management of patients with GIST is early or late tumour progression during imatinib therapy. Progression can be seen by the presence of tumour growth on CT or MRI scans. In a small subset of patients, primary resistance to imatinib is manifested by initial disease progression with therapy. This may be due to primary resistant mutations such as the exon 18 mutation D842V of PDGFRα involving the kinase activation loop of the receptor, or the absence of any KIT or PDGFRα mutation at all, suggesting that these tumours are biologically different and less reliant on kinases [33] . Another explanation is the use of the standard dose of imatinib in the presence of an exon 9 mutation. In contrast, secondary resistance to imatinib may occur after initial stabilization and regression of the disease and is often noted focally. On imaging, this secondary GIST resistance is heralded by the appearance of a new nodular focus within a previously responsive hypodense mass. This change reflects the emergence of a resistant clonal nodule in the surrounding tumour that itself remains responsive to imatinib. Current evidence suggests that the mechanism of imatinib resistance in GIST, characterized by these intratumoural nodules, is the emergence of secondary mutations in tumour genotype [34, 35] . Those mutations could alter the ATP binding site in such a way that imatinib can no longer bind and so cannot inhibit the activation of the kinases. Compounds such as sunitinib and regorafinib have been shown to be effective in patients resistant or intolerant to imatinib [36] [37] [38] [39] .
In conclusion, the introduction of the TKI imatinib as a targeted therapy for treating GIST serves as a model for other therapies in different tumour types. With imatinib it was shown for the first time that certain mutations could be a predictive factor, and that secondary mutations can be related to resistance. These insights from the development of imatinib have been helpful in finding effective treatments for many other cancers.
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